Melanotan II

Overview

Melanotan II is a synthetic, non-selective agonist of melanocortin receptors (activating MC1R, MC3R, MC4R, and MC5R simultaneously), originally studied at the University of Arizona as a potential sunless-tanning and photoprotective agent. Because it activates multiple melanocortin receptor subtypes rather than a single target, it produces a broad set of effects beyond pigmentation — including on appetite and sexual arousal pathways (MC3R/MC4R) — which the original researchers noted as a limitation relative to more selective candidates.

Proposed Mechanism of Action

MT-II agonizes MC1R on melanocytes, stimulating melanin production and skin pigmentation. Its lack of receptor selectivity is the mechanistic basis for the off-target effects (spontaneous erections, nausea, appetite suppression) documented in the original phase-I trial.

Research Context

The Dorr et al. (1996) pilot study is a small, early-phase human dose-escalation trial — not a large efficacy or safety trial, and MT-II has not progressed to FDA approval for any indication (its more receptor-selective successor compound, bremelanotide/PT-141, took a different development path — see our PT-141 profile). The Nelson et al. (2012) case report documents a real-world adverse event: a patient who self-administered 6 mg (roughly six times the phase-I starting dose) developed systemic toxicity and rhabdomyolysis, requiring ICU admission.

Limitations of the Current Evidence

• Melanotan II is not an FDA-approved drug and is not regulated or quality-controlled as a pharmaceutical product when sold outside a research context; the toxicity case report reflects real-world harm from unsupervised, unverified-purity use.
• The phase-I trial was small (a handful of subjects) and was designed to establish a tolerable dose range, not to demonstrate long-term safety or efficacy.